Tetra Discovery Partners

Quick facts

Phase 3 pipeline

• BPN14770/ zatolmilast · Neurology
  BPN14770 is a phosphodiesterase 4D (PDE4D) inhibitor that increases intracellular cAMP levels to enhance cognitive function and reduce neuroinflammation.
• Zatolmilast/ BPN14770

Phase 2 pipeline

• BPN14770 · Autoimmune diseases
  BPN14770 is a small molecule inhibitor of the PI3K delta subunit.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Tetra Discovery Partners portfolio CI brief
• Tetra Discovery Partners pipeline updates RSS